Phenylketoneuria therapeutic - Maze Therapeutics
Latest Information Update: 03 Feb 2023
At a glance
- Originator Maze Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Phenylketonuria
Most Recent Events
- 16 Jan 2023 Preclinical trials in Phenylketonuria in USA (unspecified route) (Maze Therapeutics pipeline, January 2023)